Literature DB >> 2178800

Effect of gram-negative endotoxin on levels of serum corticosterone, TNF alpha, circulating blood cells, and the survival of rats.

G Feuerstein1, J M Hallenbeck, B Vanatta, R Rabinovici, P Y Perera, S N Vogel.   

Abstract

The relationship between serum tumor necrosis factor (TNF alpha), circulating blood cells, plasma corticosterone (CS), and survival was studied in conscious rats injected intravenously with E. coli lipopolysaccharide (LPS, 0.0001-28.8 mg/kg). The TNF alpha response was dose-related, peaked at 90-120 min after LPS injection, and subsided 6 hr later. The CS response showed an earlier onset, prolonged (greater than 12 hr) duration, and a broader dose-response pattern. White blood cells (WBC) and platelet depletion peaked at 2-4 and 24-48 hr post-LPS, respectively; however, no changes in the cell count were observed at LPS doses which produced greater than 50% maximal increase in TNF alpha levels. Survival curves for each of the LPS doses were significantly different from the doses of LPS which elicited TNF alpha release. Systemic injection of human recombinant TNF alpha (h-rTNF alpha), which produced plasma levels of TNF alpha 10 x 10(7) U/ml, much higher than the maximal TNF alpha levels produced by LPS, 1-2 x 10(5) U/ml, failed to affect survival, plasma WBC, or hematocrit. Our data suggest that factors other than TNF alpha produced by high doses of LPS are essential in eliciting LPS-induced death.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178800

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  13 in total

1.  Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme.

Authors:  J L Masferrer; K Seibert; B Zweifel; P Needleman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice.

Authors:  M Ogata; T Matsumoto; M Kamochi; S I Yoshida; Y Mizuguchi; A Shigematsu
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  Differential inhibition of lipopolysaccharide-induced phenomena by anti-tumor necrosis factor alpha antibody.

Authors:  S N Vogel; E A Havell
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

4.  Adjuvant arthritic (AA) rats exhibit enhanced endotoxin-induced plasma TNF (EIPT) levels.

Authors:  M DiMartino; M Slivjak; K Esser; C Wolff; E Smith; R Gagnon
Journal:  Agents Actions       Date:  1993

5.  Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock.

Authors:  C Thiemermann; C C Wu; C Szabó; M Perretti; J R Vane
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival.

Authors:  A K Franks; K I Kujawa; L J Yaffe
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

7.  Similar cytokine but different coagulation responses to lipopolysaccharide injection in D-galactosamine-sensitized versus nonsensitized rats.

Authors:  S Bahrami; H Redl; G Leichtfried; Y Yu; G Schlag
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

8.  An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan.

Authors:  M Ogata; T Matsumoto; K Koga; I Takenaka; M Kamochi; T Sata; S Yoshida; A Shigematsu
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

9.  Platelet activating factor mediates interleukin-2-induced lung injury in the rat.

Authors:  R Rabinovici; M D Sofronski; J F Renz; L M Hillegas; K M Esser; J Vernick; G Feuerstein
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

10.  Tumor necrosis factor-induced mortality is reversed with cyclooxygenase inhibition.

Authors:  J R Fletcher; J N Collins; E D Graves; A Luterman; M D Williams; S D Izenberg; C B Rodning
Journal:  Ann Surg       Date:  1993-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.